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Abstract
Background: Recessive mutations in guanylate cyclase-1 (Gucy2d) are associated with severe, early onset Leber congenital
amaurosis-1(LCA1). Gucy2d encodes guanylate cyclase (GC1) is expressed in photoreceptor outer segment membranes and
produces cGMP in these cells. LCA1 patients present in infancy with severely impaired vision and extinguished
electroretinogram (ERG) but retain some photoreceptors in both their macular and peripheral retina for years. Like LCA1
patients, loss of cone function in the GC1 knockout (GC1KO) mouse precedes cone degeneration. The purpose of this study
was to test whether delivery of functional GC1 to cone cells of the postnatal GC1KO mouse could restore function to these
cells.
Methodology/Principal Findings: Serotype 5 AAV vectors containing either a photoreceptor-specific, rhodopsin kinase
(hGRK1) or ubiquitous (smCBA) promoter driving expression of wild type murine GC1 were subretinally delivered to one eye
of P14 GC1KO mice. Visual function (ERG) was analyzed in treated and untreated eyes until 3 months post injection. AAV-
treated, isogenic wild type and uninjected control mice were evaluated for restoration of visual behavior using optomotor
testing. At 3 months post injection, all animals were sacrificed, and their treated and untreated retinas assayed for
expression of GC1 and localization of cone arrestin. Cone-mediated function was restored to treated eyes of GC1KO mice
(ERG amplitudes were ,45% of normal). Treatment effect was stable for at least 3 months. Robust improvements in cone-
mediated visual behavior were also observed, with responses of treated mice being similar or identical to that of wild type
mice. AAV-vectored GC1 expression was found in photoreceptors and cone cells were preserved in treated retinas.
Conclusions/Significance: This is the first demonstration of gene-based restoration of both visual function/vision-elicited
behavior and cone preservation in a mammalian model of GC1 deficiency. Importantly, results were obtained using a well
characterized, clinically relevant AAV vector. These results lay the ground work for the development of an AAV-based gene
therapy vector for the treatment of LCA1.
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Introduction
Leber congenital amaurosis (LCA) is an autosomal recessive
group of diseases that represent the earliest and most severe form
of all inherited retinal dystrophies. The first gene implicated in the
onset of this genetically and clinically heterogeneous disease, and
therefore assigned to the LCA1 locus was retinal-specific Guanylate
cyclase-1 (Gucy2d) [1]. Gucy2d encodes the retina- specific protein
guanylate cyclase (GC1) which is expressed in both cone and rod
photoreceptor disc membranes [2]–[3] and plays a role in the
regulation of cGMP and Ca
2+ levels within these cells. Following
light stimulation, levels of cGMP within photoreceptor outer
segments rapidly fall due to hydrolysis by cGMP phosphodiester-
ase (PDE). This reduction of cGMP leads to a closure of cGMP-
gated channels, reduced Ca
2+ influx and hyperpolarization of the
cell. This decrease in intracellular Ca
2+ stimulates return of light-
stimulated photoreceptors to the dark state via its interaction with
guanylate cyclase (GC) activating proteins (GCAPs), a family of
calcium binding proteins that regulate the activity of GC. In the
dark adapted photoreceptor, Ca
2+ bound GCAPs inhibit the
activity of GC. Upon light stimulation, however, Ca
2+-free GCAPs
stimulate GC activity which increases cGMP levels, reopens
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[4]. Mutations which reduce or abolish the ability of GC to
replenish intracellular cGMP and reopen cGMP-gated cation
channels, as is the case in LCA1, are thought to create the
biochemical equivalent of chronic light exposure in rod and cone
photoreceptors [5].
Mutations in Gucy2d account for as many as 20% of all cases of
LCA making it one of the leading causes of this disease [1],[6],[7]
The number of patients affected by LCA1 is approximately double
that affected by the well known RPE65 version of LCA (LCA2)
[8],[9]. Diagnosis of LCA1 is typically made within the first few
months of life and is characterized by severely impaired vision,
extinguished electroretinogram (ERG) and pendular nystagmus
[8], [10]. Despite these functional deficits, LCA1 patients present
with normal fundus [8] and retain some rods and cones in both
their macular and peripheral retina for years [6], [11]–[12]. Using
spectral-domain optical coherence tomography (SDOCT) to scan
the central macular and perifoveal areas, a recent study revealed
that LCA1 patients (age range, 20–53 years) retained all 6 retinal
layers with a visible photoreceptor inner/outer segment juncture
[12]. Maintenance of retinal structure in LCA1 is unlike other
forms of the disease which exhibit marked retinal thinning that
generally worsens with age [12]. While the preservation of retinal
structure does not parallel better visual acuity in LCA1 patients, it
does suggest that they may be responsive to gene-based
therapeutic strategies that require some level of rod/cone cell
preservation.
Two animal models carrying null mutations in the GC1 gene
have been used to evaluate gene replacement therapy, the
naturally occurring GUCY1*B chicken and the guanylate-
cyclase-1 (GC1) knockout mouse [13]–[14]. The GUCY1*B
chicken is blind at hatch, exhibits extinguished scotopic (rod-
mediated) and photopic (cone-mediated) ERG and retinal
degeneration [5], [15]–[16]. Prehatch lentiviral-mediated transfer
of Gucy2d to the GUCY1*B retina restored vision to these animals
as evidenced by behavioral testing and ERG analysis [13]. Despite
the short term therapeutic success, this therapy fell short of
preserving retinal structure or function in the long term. The
transient nature of this result, obtained in a non-mammalian
species with an integrating viral vector delivered in-ovo suggested
the need for more appropriate translational studies towards the
development of clinical application. A mammalian model of GC1
deficiency, the GC1KO mouse exhibits cone photoreceptor
degeneration [17]–[18]. Like LCA1 patients, loss of cone function
in this mouse model precedes cone degeneration [17]. Rod
photoreceptors in this model do not degenerate and continue to
generate ERG responses to light [17], a result likely due to the
presence of GC2, a close relative of GC1 in these cells [19]–[22].
AAV-mediated transfer of Gucy2d to the post-natal GC1KO retina
failed to restore cone ERG responses or prevent cone degeneration
[14]. In both the chicken and mouse studies which were conducted
by the same investigators, the therapeutic cDNA was of bovine
origin, the species historically used in biochemical assays
evaluating GC1 function [13], [23]. This raises the question of
whether the heterologous nature of these gene transfer strategies
was the reason for their incomplete success.
In the present series of experiments, we evaluated whether
delivery of a species-specific (murine) version of GC1 to cones of
the postnatal GC1KO mouse could restore function to and
preserve these cells. Serotype 5 AAV vectors were used to
deliver mGC1 to photoreceptors of postnatal day 14 (P14)
GC1KO mice. The results reported herein are the first
demonstration that gene therapy is capable of restoring visual
function and visually evoked behavior to a mammalian model of
GC1 deficiency. Importantly, results were obtained following
postnatal delivery of a well characterized, clinically relevant
AAV vector. These results lay the groundwork for the
development of an AAV-based gene therapy vector for
treatment of LCA1.
Materials and Methods
Experimental Animals
GC1+/2 heterozygote embryos were removed from a
cryopreserved stock at The Jackson Laboratory (Bar Harbor,
ME). Heterozygotes were mated at the University of Florida to
produce GC1 KO (2/2) and isogenic +/+ control offspring. All
mice were bred and maintained in the University of Florida
Health Science Center Animal Care Services Facility under a
12hr/12hr light/dark cycle. Food and water were available ad
libitum. All experiments were approved by the University of
Florida’s Institutional Animal Care and Use Committee and
conducted in accordance with the ARVO Statement for the Use
of Animals in Ophthalmic and Vision Research and NIH
regulations.
Construction of AAV vectors
Serotype 5 Adeno-associated virus (AAV5) vectors were used to
deliver murine GC1 (mGC1) as they have been shown to exhibit
robust transduction efficiency and relatively quick expression in
retinal photoreceptors [24]. Both a cell-specific and ubiquitous
promoter were selected to drive expression of mGC1 (generously
provided by Joseph Besharse). A promoter for the cell-specific, G
protein-coupled receptor kinase 1 (GRK1), also known as
rhodopsin kinase was chosen for its ability to specifically target
robust transgene expression in rod and cone photoreceptors when
used in conjunction with AAV [25]. The ubiquitous smCBA
promoter which exhibits a similar expression pattern to full-length
CBA in retina was chosen for its ability to efficiently target the
neural retina [14]. Polymerase chain reaction utilizing forward
primer 59AAAAGCGGCCGCATGAGCGCTTGGCTCCTGC-
CAGCC39 and reverse primer 59 AAAAGCGGCCGCT-
CACTTCCCAGTAAACTGGCCTGG39 was used to amplify
mGC1 from a plasmid containing an mGC1-eGFP fusion [26].
The resulting fragment was cloned into pCRblunt plasmid
(Invitrogen, Carlsbad, CA) and then sequence verified. AAV
vector plasmid containing smCBA driving expression of mGC1
(pTR-smCBA-mGC1) was created by replacing full length CBA
with smCBA in plasmid pTR-CB
SB-hRPE65 [27] via EcoR I
digest and ligation. Subsequently, hRPE65 was replaced with
mGC1 via Not I digestion and ligation, resulting in the creation of
pTR-smCBA-mGC1. AAV vector plasmid containing human
GRK1 promoter driving expression of mGC1, pTR-GRK1-
mGC1 was created by removing hGFP from pTR-hGRK1-hGFP
[28] and replacing it with mGC1 via Not I digest and ligation.
AAV vectors were packaged according to previously published
methods [14]. Viral particles were resuspended in Balanced Salt
Solution (Alcon, Fort Worth, TX) and titered by quantitative real-
time PCR [27]. Resulting titers were 4.69610
12 vg/ml and
4.12610
13 vg/ml for AAV5-smCBA-mGC1 and AAV5-hGRK1-
mGC1, respectively.
Subretinal Injections
One ml of AAV5-GRK1-mGC1 (4.12610
10 delivered vector
genomes) or AAV5-smCBA-mGC1 (4.69610
9 delivered vector
genomes) was injected subretinally at postnatal day 14 (P14) to the
right eye of each GC1KO mouse, leaving the left eye as a
contralateral control. Subretinal injections were performed as
Gene Therapy GC1 Deficiency
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only on animals which received comparable, successful injections
(.60% retinal detachment and minimal complications). It is well
established that the area of retinal detachment corresponds to the
area of viral transduction [29], [31].
Electroretinographic analysis
Electroretinograms of treated GC1KO (n=14) and isogenic
+/+ controls (n=2) were recorded using a PC-based control and
recording unit (Toennies Multiliner Vision; Jaeger/Toennies,
Ho ¨chberg, Germany) according to methods previously described
with minor modifications [14]. Initial ERG measurements were
recorded at 4 weeks post injection, and every subsequent 2 weeks
thereafter until 3 months post-injection (the latest time point
evaluated in this study). Age matched +/+ isogenic controls were
recorded alongside treated animals at every time point. Mice were
dark-adapted overnight (more than 12 hours) and anesthetized
with a mixture of 100 mg/kg ketamine, 20 mg/kg xylazine and
saline in a 1:1:5 ratio, respectively. Pupils were dilated with 1%
tropicamide and 2.5% phenylephrine hydrochloride. A heated
circulating water bath was used to maintain the body temperature
at 38uC. Hydroxypropyl methylcellulose 2.5% was applied to each
eye to prevent corneal dehydration. Full field ERGs were recorded
using custom, gold wire loop corneal electrodes. Reference and
ground electrodes were placed subcutaneously between the eyes
and in the tail, respectively. Scotopic rod recordings were elicited
with a series of white flashes of seven increasing intensities
(.01 mcds/m
2 to 5 cds/m
2). Interstimulus intervals for low
intensity stimuli were 1.1 second. At the three highest intensities
(100 mcds/m
2, 1 cds/m
2 and 5 cds/m
2), instimulus intervals were
2.5, 5.0 and 20.0 seconds, respectively. Ten responses were
recorded and averaged at each intensity. Mice were then light
adapted to a 100 cds/m
2 white background for 2 minutes.
Photopic cone responses were elicited with a series of five
increasing light intensities (100mcds/m
2 to 12 cds/m
2). Fifty
responses were recorded and averaged at each intensity. All stimuli
were presented in the presence of the 100 cds/m
2 background. B-
wave amplitudes were defined as the difference between the a-
wave troughs to the positive peaks of each waveform. Photopic b-
wave maximum amplitudes (those generated at 12 cds/m
2) of all
smCBA-mGC1- treated (n=6) and hGRK1-mGC1- treated
(n=8) GC1KO (both treated and untreated eyes) and isogenic
+/+ control mice were averaged and used to generate standard
errors. These calculations were made at every time point (4 weeks-
13 weeks post injection). This data was imported into Sigma Plot
for final graphical presentation. The paired t-test was used to
calculate P-values between treated and untreated eyes within each
promoter group (smCBA or hGRK1) and between each promoter
group over time (4 weeks post-injection vs. 3 months post-
injection). The standard t-test was used to calculate P-values
between smCBA-mGC1 vs. hGRK1-mGC1 treated eyes. Signif-
icant difference was defined as a P-value,0.05. Because a subset
of mice from each treated group was sent to SUNY Upstate for
behavioral analyses, the total number of mice averaged and
presented at each time point in results differs. Three mice from the
smCBA-mGC1-treated group were sent for optomotor testing,
leaving an n of 3 mice used for ERG analysis during the 8, 10 and
12 week measurements. Two mice from the hGRK1-mGC1-
treated group were sent for optomotor testing, leaving an n of 6
used for ERG analysis during the 6, 8, 10 and 12 week
measurements. All mice sent for behavioral analysis were analyzed
subsequently by ERG at 13 weeks post injection upon their return
to the University of Florida (smCBA-mGC1: n=3, hGRK1-
mGC1: n=2).
Optomotor Testing
Photopic visual acuities and contrast sensitivities of treated and
untreated GC1KO mouse eyes were measured using a two-
alternative forced choice paradigm as described previously
[32],[33]. To test the sensitivity of individual eyes from the same
animal we took advantage of the fact that mouse vision has
minimal binocular overlap and that the left eye is more sensitive to
clockwise rotation and the right to counter-clockwise rotation [34].
Thus in our ‘‘randomize-separate’’ optomotor protocol, each eye’s
acuity and contrast sensitivity threshold was determined separately
and simultaneously via stepwise functions for correct responses in
both the clockwise and counter-clockwise directions. Correct
detection of patterns rotating in the clockwise direction was driven
primarily by visual signals originating from the left eye and correct
responses in the counterclockwise direction were derived from
visual signals originating from the right eye. Acuity was defined the
highest spatial frequency (100% contrast) yielding a threshold
response, and contrast sensitivity was defined as 100 divided by the
lowest percent contrast yielding a threshold response. For photopic
acuity, the initial stimulus was a 0.200 cycles/degree sinusoidal
pattern with a fixed 100% contrast. For photopic contrast
sensitivity measurements, the initial pattern was presented at
100% contrast, with a fixed spatial frequency of 0.128 cycles/
degree. Photopic vision was measured at a mean luminance of
70 cd/m
2. Visual acuities and contrast sensitivities were measured
for both eyes of each mouse four to six times over a period of 1
week. Age matched, isogenic +/+ control animals (M1, M2) and
naı ¨ve GC1KO mice (M3, M4) are presented along with the
smCBA-mGC1-treated (M5, M6, M7) and hGRK1-mGC1-
treated mice (M8, M9). Cone-mediated ERG amplitudes gener-
ated from a 12 cds/m
2 stimulus of all mice (M1–M9) are
presented alongside the behavior results. Unpaired t-tests were
carried out on acuity and percent contrast values to determine
significance of results.
Tissue Preparation
Three months post injection, P14-treated GC1KO mice were
sacrificed. The limbus of injected and uninjected eyes was marked
with a hot needle at the 12 o’clock position, facilitating orientation.
Enucleation was performed under dim red light and eyes were
placed immediately in 4% paraformaldehyde. Eyes that were to be
used for cryosectioning were prepared according to previously
described methods [14]. Briefly, corneas were removed from each
eye, leaving the lens inside the remaining eye cup. A small ‘‘V’’
shaped cut was made into the sclera adjacent to the burned limbus
to maintain orientation. After overnight fixation, the lens and
vitreous were removed. The remaining retina/RPE-containing
eyecup was placed in 30% sucrose in PBS for at least 1 hour at 4u.
Eyecups were then placed in cryostat compound (Tissue Tek OCT
4583; Sakura Finetek USA, Inc., Torrance, CA) and snap frozen
in a bath of dry ice/ethanol. Eyes were serially sectioned at 10
microns with a cryostat (Microtome HM550; Walldorf, Germany).
Eyes that were to be used for whole mount analysis were prepared
according to previously described methods [35]. Orientation was
achieved as previously mentioned. After overnight fixation,
cornea, lens, vitreous and retinal pigment epithelia were removed
from each eye without disturbing the retina. A cut was made in the
superior (dorsal) portion of the retina adjacent to the original
limbus burn to maintain orientation.
Immunohistochemistry and Microscopy
Retinal cryosections and whole mounts were washed 3 times in
16PBS. Samples were then incubated in 0.5% Triton X-100 for
1 hour in the dark at room temperature, blocked in a solution of
Gene Therapy GC1 Deficiency
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temperature and incubated overnight at 37u with a rabbit
polyclonal GC1 antibody (1:200, sc-50512, Santa Cruz Biotech-
nology, Inc.), rabbit polyclonal cone arrestin antibody (‘‘Lumij’’
1:1000, generously provided by Dr. Cheryl Craft) or a lectin PNA
conjugated to Alexa Fluor 488 (1:200, L21409, Invitrogen) diluted
in 0.3% Triton X-100/1% BSA. Retinal whole mounts were
incubated overnight at room temperature with the same cone
arrestin antibody, diluted 1:1000 in 0.3% Triton X-100/1% BSA.
Following primary incubation, retinal sections and whole mounts
were washed 3 times with 16 PBS then incubated for 1 hour at
room temperature with IgG secondary antibodies tagged with
either Alexa-594 or Alexa-488 fluorophore (Molecular Probes,
Eugene OR) diluted 1:500 in 16PBS and washed with 16PBS.
Retinal sections were counterstained with 49,6 9-diamino-2-
phenylindole (DAPI) for 5 minutes at room temperature. After a
final rinse with 16 PBS and water, sections were mouted in an
aqueous-based media (DAKO) and coverslipped. Retinal whole
mounts were oriented on slides with the superior (dorsal) portion of
the retina positioned at 12- o’clock. Samples were mounted in
DAKO and coverslipped. Retinal sections were analyzed by
confocal microscopy (Leica TCS SP2 AOBS Spectral Confocal
Microscope equipped with LCS Version 2.61, Build 1537
software). All images were taken with identical exposure settings
at either 206or 636magnification. Excitation wavelengths used
for DAPI, GC1 and cone arrestin stains were 405, 488 and 594,
respectively. Emission spectra were 440–470nm, 500–535nm and
605–660nm, respectively. Retinal whole mounts were analyzed
with a widefield fluorescent microscope (Zeiss Axioplan 2)
equipped with a QImaging Retiga 4000R Camera and QImaging
QCapture Pro software. Quadrants of each whole mount were
imaged at 56under identical exposure settings and then merged
together in Adobe Photoshop.
Image Analysis
Cone photoreceptor densities were analyzed in retinal whole
mounts by counting cells labeled with secondary fluorophore
directed against cone arrestin antibody in the central and inferior
retina using ImageJ software (NIH, Bethesda, MD, USA). Five
squares (500 mm
2) were placed over identical areas in central and
inferior retina of both treated and untreated GC1KO eyes. For
central retina, squares were placed at an equal eccentricity around
the optic nerve head in all eyes (125 mm). Cone photoreceptors
were counted in each respective retinal area, values were averaged
and standard deviations calculated. The standard t-test was used to
calculate P-values between desired samples. Significant difference
was defined as a P-value,0.05.
Results
Both the photoreceptor-specific human RK promoter and
ubiquitous smCBA promoter drive mGC1 transgene
expression in rods and cones of GC1KO mice
GC1- deficiency affects both rod and cone photoreceptors in
LCA1 patients. We therefore chose the photoreceptor-specific
human RK promoter and the ubiquitous smCBA promoter for
this study as a means to target both cell types. The human RK
promoter was chosen for its small size and ability to efficiently
drive transgene expression specifically in photoreceptor cells [25],
[36]–[37]. Immunostaining of GC1KO retinas 3 months post-
treatment with AAV5-hGRK1-mGC1 revealed that this promoter
drove robust GC1 expression exclusively in photoreceptor (rod
and cone) outer segments. A representative image of a retinal cross
section from an eye injected with this therapeutic vector
(Figure 1A) shows intense GC1 staining in the OS layer whereas
the contralateral, untreated eye lacks any GC1 expression
(Figure 1B). The smCBA promoter also efficiently drove GC1
expression in photoreceptor cells. Photoreceptor OS exhibited
robust smCBA-mediated GC1 expression in treated eyes
(Figure 1C), relative to the contralateral, untreated eye
(Figure 1D). Levels of hGRK1 and smCBA-mediated GC1
expression approached those seen in isogenic, +/+ control eyes
(Figure 1E). GC1 expression in hGRK1-mGC1-treated eyes was
restricted to outer segments. In smCBA-mGC1- treated eyes, GC1
expression was occasionally found in photoreceptor inner
segments and cell bodies of the outer nuclear layer (Figure 1F,
arrows). Notably however, neither promoter construct drove
therapeutic GC1 expression in retinal cells other than photore-
ceptors. This lack of off-target expression could be relevant to the
development of safe future clinical applications. A representative
section stained for GC1 was also stained with lectin PNA which
labels cone outer segment sheaths. Figure 2 shows an overlay of
GC1 (red) and PNA (green) expression in cone cells. GC1
expression was not exclusive to cones, however, proving that
therapeutic transgene is expressed in both rods and cones of
treated GC1KO mice (Figure 2).
Photoreceptor function (ERG) is restored in AAV-treated
GC1KO mice
It was previously reported that cone responses in the GC1KO
mouse are barely detectable by 1 month of age [17]. Here we show
that P14-treatment of this mouse with an AAV vector carrying the
mouse GC1 gene under the control of either a photoreceptor-
specific (hGRK1) or ubiquitous (smCBA) promoter led to
substantial restoration of cone photoreceptor function as measured
by ERG. Representative cone traces (Figure 3A) as well as the
average photopic b-wave amplitudes (Figure 4) from hGRK1-
mGC1-treated, smCBA-mGC1-treated, GC1KO and isogenic
+/+ controls show that cone function in treated eyes is restored to
approximately 45% of normal at four weeks post injection. Similar
to previous reports, cone responses in contralateral, untreated eyes
were undetectable at this time point. At 4 weeks post injection, the
average cone-mediated b-wave amplitude in smCBA-mGC1-
treated eyes (65.1 mV) was significantly higher (P=.006) than that
in the untreated eyes (3.9 mV). The average cone mediated b-wave
amplitude in hGRK1-mGC1-treated eyes (59.1 mV) was signifi-
cantly higher (P,.001) than that in untreated eyes (3.2 mV). The
level of restoration achieved four weeks following delivery of the
photoreceptor-specific hGRK1-mGC1 vector was not significantly
different from that achieved with the ubiquitous promoter-
containing smCBA-mGC1 vector (P=.604). At 3 months post
injection, the average cone-mediated b-wave amplitude in
smCBA-mGC1-treated eyes (53.3 mV) was significantly higher
(P,.001) than that in the untreated eyes (2.8 mV). The average
cone mediated b-wave amplitude in hGRK1-mGC1-treated eyes
(45.3 mV) was significantly higher (P,.001) than that in untreated
eyes (3.4 mV). The level of restoration achieved 3 months following
delivery of the photoreceptor-specific GRK1-mGC1 vector was
not significantly different from that achieved with the ubiquitous
promoter-containing smCBA-mGC1 vector (P=.331). Both
promoters conferred similar levels of functional restoration to
cones in treated eyes of the GC1KO mouse in the short term.
Importantly, restoration of cone photoreceptor function remained
stable for 3 months (the latest time point evaluated in this study)
(Figures 3 and 4). There was no significant difference in photopic
b-wave amplitudes of smCBA-mGC1-treated or hGRK1-mGC1-
treated eyes between 4 weeks and 3 months post treatment
(P=0.174 and 0.125, respectively).
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of various retinal disorders including other forms of LCA [36] were
also determined. While such measurements cannot be reliably
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cone b-wave implicit times in AAV-mGC1 treated and isogenic +/+
control mice. At 4 weeks post injection, there was no significant
difference between cone b-wave implicit times in treated and +/+
control eyes (P=0.884); average values in AAV-mGC1-treated and
+/+ eyes at this time point were 50.8 ms and 50.4 ms, respectively.
At 3 months post injection, there was also no significant difference
between the two groups (P=0.697); averages of all cone b-wave
implicit times in treated and +/+ control eyes were 59.7 ms and
Figure 1. AAV-mediated GC1 expression in photoreceptors of the GC1KO mouse. AAV5-hGRK1-mGC1 drives expression of GC1 in
photoreceptor outer segments of GC1KO mice. (A). No GC1 expression is seen in the untreated, contralateral control eye (B). AAV5-smCBA-mGC1
drives expression of GC1 in photoreceptor outer segments (C) and occasionally in photoreceptor cell bodies (arrows in F). No such GC1 expression is
seen in the untreated, contralateral control eye (D). Levels of therapeutic transgene expression in the AAV5-mGC1-treated eyes are only slightly less
than that seen in isogenic GC1+/+ control eyes (E). All retinas were taken from mice 3 months post treatment or age matched untreated controls.
Scale bars in A=100mm, F=25mm. OS-outer segments, IS-inner segments, ONL-outer nuclear layer.
doi:10.1371/journal.pone.0011306.g001
Gene Therapy GC1 Deficiency
PLoS ONE | www.plosone.org 5 June 2010 | Volume 5 | Issue 6 | e11306Figure 2. AAV5-mGC1 drives expression of GC1 in both rod and cone photoreceptors. Representative retinal section from a GC1KO eye
injected with AAV5-smCBA-mGC1 stained for GC1 (red) and PNA lectin (green) reveals GC1 expression in cone outer segments (yellow overlay) as well
as in rod outer segments (red alone). hGRK1-mGC1 injected eyes revealed the same pattern (data not shown).
doi:10.1371/journal.pone.0011306.g002
Figure 3. AAV5-mGC1 restores retinal function to cone photoreceptors of the GC1KO mouse. Representative cone (left column)- and rod
(right column)-mediated ERG traces from GC1 +/+ (upper waveforms), untreated GC1KO (middle waveforms) and AAV5-mGC1-treated (bottom
waveforms) mice. For the middle and bottom waveforms in each panel, red traces correspond to eyes injected with AAV5-smCBA-mGC1 (bottom)
and their uninjected contralateral eyes (middle) and black traces correspond to eyes injected with AAV5-hGRK1-mGC1 (bottom) and uninjected
contralateral eyes (middle). Cone responses in AAV5-mGC1-treated eyes are restored to approximately 45% of normal amplitude.
doi:10.1371/journal.pone.0011306.g003
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GC1KO retina, as determined by implicit time measurements
appeared to be normal and stable in the short term.
It was previously reported that rod ERGs in the GC1KO mouse
show alterations by 1 month of age, with the rod a-wave and b-
wave both markedly reduced [17]. This loss plateaus at 5 months
of age with responses approximately 50–70% that of a WT mouse.
While we observed some instances of AAV-mGC1-mediated
improvements in treated eyes of GC1KO mice relative to
untreated controls (example seen in Figure 3), this result was not
as consistent as that seen for the cone-mediated responses.
Additional studies are required to elucidate how effective this
therapy will be at restoring rod-mediated ERGs.
Cone mediated visual acuity and contrast sensitivity are
restored in AAV-treated GC1KO mice
Optomotor analysis revealed that eyes of GC1KO mice
treated with either smCBA-mGC1 (Figure 5A: M5, M6, M7) or
hGRK1-mGC1 (Figure 5: M8, M9) responded significantly
better than untreated eyes under all photopic, cone-mediated
conditions. Untreated GC1KO eyes perform poorly with a
visual acuity of 0.16360.040 cycles per degree (Figure 3B, 3C,
Figure 4. Average photopic b-wave maximum amplitudes as a function of both flash intensity and time after treatment. Responses of
GC1KO, isogenic +/+ controls, AAV5-smCBA-mGC1-treated (A) and AAV5-hGRK1-mGC1-treated (B) GC1KO mice reveal that cone responses in both
smCBA-mGC1 and hGRK1-mGC1-treated mice are approximately 45% of normal for at least 3 months post injection (the longest time point evaluated
in this study).
doi:10.1371/journal.pone.0011306.g004
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eyes (Figure 5: M1, M2) respond significantly better, showing an
average acuity of 0.41860.046 cycles per degree (black bar,
n=4 eyes). AAV-mGC1-treated eyes (Figure 5: M5–M9) have
an average acuity of 0.39260.077 cycles per degree (red bar,
n=5 eyes), a level essentially identical to control +/+ eyes and
significantly better than untreated GC1KO eyes (P,0.0001).
Photopic contrast sensitivities (Figure 5A, 5B) paralleled the
photopic acuity results, with AAV-mGC1-treated eyes (contrast
sensitivity of 11.9067.37, n=5 eyes) showing contrast thresh-
olds identical to +/+ mice (11.9463.03, n=4 eyes). Again,
GC1KO eyes treated at P14 with AAV-mGC1 performed
Figure 5. Optomotor analysis of visual function restoration in GC1KO mice treated with either AAV5-smCBA-mGC1 or AAV5-
hGRK1-mGC1. M1–M9 correspond to the nine mice used for testing. Photopic acuities and contrast sensitivities of GC1+/+ control mice (M1, M2),
naı ¨ve GC1KO (M3, M4), smCBA-mGC1-treated (M5, M6, M7) and hGRK1-mGC1-treated GC1KO (M8, M9) mice reveal that treated mice behave like
normal sighted mice (A, B). Average values for photopic visual acuity and contrast sensitivity of all GC1+/+ eyes (n=4), untreated GC1KO eyes (n=9)
and AAV5-mGC1-treated eyes (n=5) are shown (B) (*=P,0.0001). Cone-mediated ERG responses from each mouse (M1–M9) are shown for
comparison (C).
doi:10.1371/journal.pone.0011306.g005
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contrast sensitivity of 1.2760.31 (n=9, P,0.0001). In all
photopic tests, untreated GC1KO eyes perform extremely
poorly, essentially equivalent to having no cone-mediated
function. Statistical comparisons of these measurements are
shown in Table 1. Cone-mediated ERG traces of all GC1+/+
(M1, M2), GC1KO (M3, M4), smCBA-mGC1-treated (M5, M5,
M7) and hGRK1-mGC1-treated (M8, M9) mice used in the
optomotor analyses are shown in Figure 5C to relate visual
function (optmotor behavior) to retinal function (ERG).
Rod ERG amplitudes are partially preserved in the GC1KO
mouse. Studies have shown that even very small ERG
amplitudes can translate into robust visual behavior [13] and
that ERG activity (particularly in mouse) does not always
reliably predict behavioral performance [38]. In fact, some
LCA2 patients who received AAV-RPE65 therapy were found
to exhibit behavioral restoration despite a complete lack of ERG
response [39]–[40]. Optomotor testing revealed that scotopic,
rod-mediated visual acuities and contrast sensitivities of
untreated GC1KO eyes are very similar to isogenic, +/+
controls (data not shown). For this reason, it was impossible to
compare rod-mediated visual restoration in treated vs. untreated
eyes using these behavior tests. It is likely therefore that any
future studies of the effects of AAV-mediated mGC1 expression
on rod function in this mouse model will have to be evaluated at
the level of ERG.
Cone photoreceptors are preserved in AAV-mGC1-
treated GC1KO mice
Representative untreated GC1KO retinal sections immuno-
stained with an antibody against cone arrestin revealed the
characteristic disorganization and detachment of cone outer
segments (Figure 6B). On the contrary, cone outer segments were
intact and cone arrestin distribution appeared normal in treated
GC1KO and +/+ retinal sections (Figure 6A,C,D, respectively).
While not quantified in these retinal sections, these eyes also
exhibit an apparent increase in cone cell densities relative to
untreated controls. To quantify cone cell abundance, treated mice
were sacrificed three months post-injection and retinal whole
mounts from their treated and untreated eyes stained with an
antibody against cone arrestin. Qualitatively, it appeared that cone
photoreceptors were preserved as a result of treatment with both
the smCBA-mGC1 and hGRK1-mGC1 vectors (Figure 7).
Because cone cell loss progresses from central to peripheral retina
(most notably inferior hemisphere) in the GC1KO mouse [18], we
focused on comparing cone counts in these two areas. Cone cell
quantification revealed a statistically significant difference in the
cone densities of treated vs. untreated eyes. Cones were
significantly more abundant in the central and inferior retinas of
a representative hGRK1-mGC1-treated retina relative to untreat-
ed, contralateral control (P,0.001 and ,0.001, respectively)
(Figure 7A). Similar differences were seen in central and inferior
areas of a representative smCBA-mGC1-treated retina and its
contralateral control (P=0.008 and ,0.001, respectively)
(Figure 7B). Raw cone cell counts from each respective whole
mount are found in Table S1. P14- treatment of GC1KO mice
with either therapeutic vector is therefore capable of preserving
cone photoreceptor structure for at least three months (the longest
time point evaluated in this study), a result we anticipated given
the robust electrophysiological and behavioral restoration that also
was observed.
Discussion
This is the first demonstration of gene-based restoration of both
visual function/vision-elicited behavior and cone preservation in a
mammalian model of GC1 deficiency. Importantly, results were
obtained using a well characterized, clinically relevant AAV
vector. Our results build upon two previous attempts to rescue
vision in animal models of GC1 deficiency, both of which reported
incomplete success [13]–[14]. Our study differs in that the species-
specific (murine) GC1 cDNA was incorporated into the therapeu-
tic vector. Why bovine GC1 failed to restore retinal function or
visual behavior to the GC1KO mouse in previous studies remains
unclear.
Three ongoing clinical trials for Rpe65-LCA (LCA2) have
demonstrated the ability to target a therapeutic transgene to the
retinal pigment epithelium thereby restoring retinal function and
visually-evoked behavior to patients [31],[39],[40],[45]. However,
the need to efficiently target therapeutic vectors to photoreceptor
cells is required for the treatment of many other retinal disorders.
Restoration of visual behavior following cone-specific targeting of
a therapeutic transgene has been reported in several animal
models of cone dysfunction [33],[46]–[47]. Our findings add to
this array of gene therapy tools because they are the first
demonstration that visual behavior can be restored to an animal
model following delivery of a gene targeted to both rod and cone
photoreceptors, not just cones. This was achieved through the use
of a serotype 5 AAV vector which has proven effective at targeting
photoreceptors in a number of animal species including mouse,
dog and monkey [33],[46]–[50]. Our methods differ from recent
Table 1. Statistical comparison of the photopic visual
functions of +/+, P14-treated and untreated GC1KO mouse
eyes as measured by optomotor behavior.
Photopic Acuity
WT Tx no Tx
Number of Values 4 5 9
Mean 0.4183 0.3919 0.163
Standard Deviation 0.0456 0.07731 0.03954
P-value
WT vs Tx 0.5671 Not significant
WT vs no Tx ,0.0001 *
Tx vs no Tx ,0.0001 *
Photopic Contrast Sensitivity
WT Tx no Tx
Number of values 4 5 9
Mean 11.94 11.16 1.27
Standard Deviation 3.03 7.37 0.31
P-value
WT vs Tx 0.4186 Not significant
WT vs no Tx ,0.0001 *
Tx vs no Tx ,0.0001 *
Under photopic conditions, P14 treatment with either AAV5-smCBA-mGC1 or
AAV5-hGRK1-mGC1 produces acuity and contrast sensitivity similar to normal
GC1+/+ animals. Treated eyes have significantly better acuity and contrast
sensitivity than untreated GC1KO eyes. Each mouse was tested for 4–6 trials per
condition. Data from each animal was then averaged to obtain the means for
each condition. The standard deviation listed is the standard deviation of the
individual mouse means. P-values were calculated using an unpaired t-test.
*P,0.0001.
doi:10.1371/journal.pone.0011306.t001
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AIPL1-LCA [36]–[37] and RPGRIP-LCA [51] which employed
serotype 8 AAV as a means to confer therapy. While AAV5 has a
slower onset of transgene expression than AAV8 [52], there is
evidence that AAV8 has the increased potential for transfer across
synapses which may limit its use for photoreceptor-targeted gene
therapy in humans [53]. Our results suggest that the well-
characterized AAV5 vector is sufficient for targeting therapy to
photoreceptor cells.
Promoter choice is another vital component of any gene
replacement strategy. For the purposes of targeting expression to
photoreceptors, we chose to use the photoreceptor-specific
hGRK1 promoter as well as the well-characterized, ubiquitous
smCBA promoter. Both drove murine GC1 expression exclu-
sively in photoreceptor cells. Similar to previous reports, hGRK1-
mediated transgene expression was limited to photoreceptor cells
[36]–[37]. More specifically, GC1 expression was found only in
photoreceptorouter segments. smCBA-mediated GC1 expression
was similar with an added rare presence of the transgene product
in photoreceptor inner segments and cell bodies. However, like
the hGRK1 vector, the majority of transgene expression was
localized to photoreceptor outer segments. Neither promoter
drove any off-target expression suggesting that any expression
from the smCBA vector in RPE cells is negligible or very
inefficient, perhaps due to the instability of mGC1 within the
context of the incorrect retinal cell type. A recent study showed
that, when used in conjunction with AAV, hGRK1 also
efficiently drove AIPL1 expression exclusively in rod and cone
photoreceptors of AIPL1 mutant mice [36]. Sun et al. (2010)
suggest this promoter would be well-suited for human applica-
tion. However, another report revealed that the specificity of
hGRK1 promoter in canine retina is quite different [28]. hGRK1
drove transgene expression exclusively in rod photoreceptors of
the canine retina, except when very high viral vector titers were
used [28]. It was speculated that the discrepancy between murine
and canine retina was due to a species-specific difference in
expression of G-protein coupled receptor kinases in rods and
cones. GRK1 is expressed in rods and cones of mice and rats, but
is only found in rods of the canine retina [54]. Desensitization of
cones in these species is modulated by GRK7, a cone-specific
isoform [54]. In monkey and human retinas, GRK1 is localized
to rods but is also co-expressed with GRK7 in cones [54]. We
postulate that the lack of redundant GRK isoforms may be
responsible for the high acitivity of hGRK1 in mouse cones [28].
However, the existence of these isoforms in human retina may
limit the ability of hGRK1 to efficiently target both cell types.
The activity of this promoter therefore deserves careful
examination in the non-human primate retina. Our study also
showed that the smCBA promoter drove no off-target transgene
expression in the GC1KO retina. This is a truncated version of
the chimeric CMV-chicken beta-actin promoter (CBA). CBA has
been shown to be safe, effective and persistent when used in proof
of concept experiments and in clinical trials of retinal disease
[14],[31],[39]–[40],[45],[49], [55]–[56] and is perhaps better
suited for translation into the clinic.
The GC1 null genotype produces a recessive cone dystrophy in
the GC1KO mouse. LCA1 patients, in addition to having cone
degeneration and extinction of photopic ERG responses also
exihibit rod degeneration and extinction of scotopic ERGs. The
phenotypic differences between mouse and man are thought to be
attributed to a species-specific dependence on GC2, a cyclase
proven to support rod function in the GC1KO mouse [22].
Indeed, a GC1/GC2 double knockout mouse phenotypically
resembles human LCA1 [22]. Additional studies will be required
to evaluate the effects of AAV-mediated GC1 expression in rod
photoreceptors. While we observed some instances of increased
rod-mediated ERG responses in treated eyes of the GC1KO
mouse, this effect was not as consistent as that seen for cone
responses upon treatment. It is possible that the treatment effect
was less obvious in rods due to residual GC2-mediated function.
For this reason, it could be informative to test our therapeutic
construct(s) in the GC1/GC2 double knockout mouse. Regardless,
it is likely that GC1 will need to be targeted to both cones and rods
of LCA1 patients. We believe our clinically relevant smCBA-
containing vector may be well suited for this task.
Finally, it is important to note that LCA1 patients maintain
photoreceptor cell bodies for decades [6],[12] and therefore may
Figure 6. Cone arrestin expression in cone photoreceptors of +/+,
GC1KO, AAV5-smCBA-mGC1-treated and AAV5-hGRK1-mGC1-
treated mice. Untreated GC1KO retinas contain characteristic disorga-
nized, detached cone outer segments (B), whereas cone outer segments
were intact and cone arrestin distribution appeared normal in treated
GC1KO(C,D)and+/+(A) retinal sections.All retinas were taken from mice3
months post treatment or age matched untreated controls. Scale bar in
D=100 mm. OS-outer segments, IS-inner segments, S-synaptic terminals.
doi:10.1371/journal.pone.0011306.g006
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fact, maintenance of macular morphology in LCA1 patients is far
better than that seen in LCA2 patients of similar age [12]. In
addition, the number of patients affected by LCA1 is approximately
double that affected by LCA2 [8], [9]. The results of three ongoing
clinical trials for LCA2 have revealed safety and efficacy [39]–[40],
[45] with some patients exhibiting visual gains sufficient to generate a
new locus of fixation or pseudo-fovea [55]. The fact that some LCA2
patients treated with AAV-RPE65 exhibited profound improvements
despite the relatively poor integrity of their retinas [55] argues
strongly for the development of an AAV-based therapy for treating
LCA1. The improved structural integrity of their retinas relative to
other LCA patients suggests that they may have even more to gain
from gene replacement therapy.
Supporting Information
Table S1 Cone cell counts in retinal whole mounts from
hGRK1-mGC1-treated, smCBA-mGC1-treated and untreated
GC1KO mouse eyes. Five samplings were taken from identical
areas of each central/inferior retina; values were averaged and
standard deviations calculated. P values were calculated between
respective groups. Standard t-tests were used to compare densities
in each eye. Significant difference was defined as P,0.05.
Figure 7. AAV-mediated GC1 expression preserves cone photoreceptors in GC1KO mice. Representative retinal whole mounts from AAV5-
hGRK1-mGC1 treated (A, right), AAV5-smCBA-mGC1-treated (B-right) and contralateral, uninjected GC1KO eyes (A and B, left) stained for cone arrestin
reveal that cone photoreceptors are preserved in GC1KO mice treated with AAV5-mGC1 for at least 3 months post treatment (the latest time point
evaluated in this study). Conecell densities were counted (see materials and methods) in central and inferiorregions of treated anduntreated GC1KO mice.
Significant differences were found in both areas following treatment with either viral vector. All retinas were taken from mice 3 months post treatment.
doi:10.1371/journal.pone.0011306.g007
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